PMID- 16620398
OWN - NLM
STAT- MEDLINE
DCOM- 20060802
LR  - 20220409
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 8
IP  - 3
DP  - 2006
TI  - Survival of TNF antagonists in spondylarthritis is better than in rheumatoid 
      arthritis. Data from the Spanish registry BIOBADASER.
PG  - R72
AB  - The aim of the present work is to compare drug survival and safety of infliximab, 
      etanercept, and adalimumab (tumor necrosis factor [TNF] antagonists) in 
      spondylarthritis (SpA) with those of rheumatoid arthritis (RA). To this purpose, 
      we analysed the data in BIOBADASER (2000-2005), a drug registry launched in 2000 
      for long-term follow-up of the safety of these biologics in rheumatic diseases. 
      The rates of drug discontinuation and adverse events (AEs) in SpA (n = 1,524) 
      were estimated and compared with those of RA (n = 4,006). Cox regression analyses 
      were used to adjust for independent factors. Total exposure to TNF antagonists 
      for SpA was 2,430 patient-years and 7,865 for RA. Drug survival in SpA was 
      significantly greater than in RA at 1, 2, and 3 years. The hazard ratio (HR) for 
      discontinuation in SpA compared with RA was 0.66 (95% confidence interval [CI], 
      0.57-0.76) after adjustment for age, gender, and use of infliximab. The 
      difference remained after controlling for the individual medication and its place 
      in the sequence of treatment. There were fewer SpA patients with AEs (17%) than 
      RA patients (26%; p < 0.001). The HR for AEs in SpA was 0.80 (95% CI, 0.70-0.91) 
      compared with RA after adjustment for age, disease duration, and use of 
      infliximab. In conclusion, due in part to a better safety profile, survival of 
      TNF antagonists in SpA is better than in RA. TNF antagonists are at present a 
      safe and effective therapeutic option for long-term treatment of patients with 
      SpA failing to respond to traditional drugs. Because chronic therapy is 
      necessary, continual review of this issue is necessary.
FAU - Carmona, Loreto
AU  - Carmona L
AD  - Research Unit, Spanish Society of Rheumatology, Madrid, Spain Marques de Duero 5, 
      28001 Madrid, Spain. lcarmona@ser.es
FAU - Gomez-Reino, Juan J
AU  - Gomez-Reino JJ
CN  - BIOBADASER Group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20060418
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Antibodies, Monoclonal/pharmacokinetics/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Arthritis, Rheumatoid/drug therapy/epidemiology/*immunology
MH  - Female
MH  - Humans
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Registries
MH  - Spain/epidemiology
MH  - Spondylarthritis/drug therapy/epidemiology/*immunology
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
PMC - PMC1526631
EDAT- 2006/04/20 09:00
MHDA- 2006/08/03 09:00
PMCR- 2006/04/18
CRDT- 2006/04/20 09:00
PHST- 2006/01/13 00:00 [received]
PHST- 2006/03/04 00:00 [revised]
PHST- 2006/03/20 00:00 [accepted]
PHST- 2006/04/20 09:00 [pubmed]
PHST- 2006/08/03 09:00 [medline]
PHST- 2006/04/20 09:00 [entrez]
PHST- 2006/04/18 00:00 [pmc-release]
AID - ar1941 [pii]
AID - 10.1186/ar1941 [doi]
PST - ppublish
SO  - Arthritis Res Ther. 2006;8(3):R72. doi: 10.1186/ar1941. Epub 2006 Apr 18.